The objectives of platelet monitoring for clinical cardiology are to evaluate new antithrombotic therapies and to track abnormal response to available antiplatelet agents. Indeed, as more is learned about the variable response to antiplatelet drugs, researchers may come to think of antiplatelet agents as they do of antibiotics, with the ultimate goal of tailoring therapy when resistance is observed in the laboratory. However, there is currently no study that permits researchers to move antiplatelet therapy resistance from a laboratory curiosity into mainstream medical practice. Indeed, there are no data that establish a cause-and-effect relationship or allow the establishment of an algorithm for treatment in response to measured platelet function inhibition.
Response to Clopidogrel Load
Fig. 13. Event rates according to level of response to loading dose of clopidogrel in patients undergoing primary PCI for STEMI (63).
Was this article helpful?